DK0673258T3 - Polymerbundne camptothecinderivater - Google Patents

Polymerbundne camptothecinderivater

Info

Publication number
DK0673258T3
DK0673258T3 DK94928387T DK94928387T DK0673258T3 DK 0673258 T3 DK0673258 T3 DK 0673258T3 DK 94928387 T DK94928387 T DK 94928387T DK 94928387 T DK94928387 T DK 94928387T DK 0673258 T3 DK0673258 T3 DK 0673258T3
Authority
DK
Denmark
Prior art keywords
pct
formula
camptothecin
units represented
hydroxy
Prior art date
Application number
DK94928387T
Other languages
Danish (da)
English (en)
Inventor
Antonino Suarato
Francesco Angelucci
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Application granted granted Critical
Publication of DK0673258T3 publication Critical patent/DK0673258T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK94928387T 1993-10-08 1994-09-21 Polymerbundne camptothecinderivater DK0673258T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939320781A GB9320781D0 (en) 1993-10-08 1993-10-08 Polymer-bound camptothecin derivatives
PCT/EP1994/003154 WO1995010304A1 (en) 1993-10-08 1994-09-21 Polymer-bound camptothecin derivatives

Publications (1)

Publication Number Publication Date
DK0673258T3 true DK0673258T3 (da) 2003-08-25

Family

ID=10743226

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94928387T DK0673258T3 (da) 1993-10-08 1994-09-21 Polymerbundne camptothecinderivater

Country Status (24)

Country Link
US (1) US5773522A (cg-RX-API-DMAC7.html)
EP (1) EP0673258B1 (cg-RX-API-DMAC7.html)
JP (1) JPH08504217A (cg-RX-API-DMAC7.html)
KR (1) KR100359005B1 (cg-RX-API-DMAC7.html)
CN (1) CN1138565C (cg-RX-API-DMAC7.html)
AT (1) ATE239507T1 (cg-RX-API-DMAC7.html)
AU (1) AU679788B2 (cg-RX-API-DMAC7.html)
CA (1) CA2150132A1 (cg-RX-API-DMAC7.html)
DE (1) DE69432627T2 (cg-RX-API-DMAC7.html)
DK (1) DK0673258T3 (cg-RX-API-DMAC7.html)
ES (1) ES2198421T3 (cg-RX-API-DMAC7.html)
FI (1) FI952746A7 (cg-RX-API-DMAC7.html)
GB (1) GB9320781D0 (cg-RX-API-DMAC7.html)
HU (1) HU215588B (cg-RX-API-DMAC7.html)
IL (1) IL111173A (cg-RX-API-DMAC7.html)
MY (1) MY116624A (cg-RX-API-DMAC7.html)
NZ (1) NZ273952A (cg-RX-API-DMAC7.html)
PL (1) PL178132B1 (cg-RX-API-DMAC7.html)
PT (1) PT673258E (cg-RX-API-DMAC7.html)
RU (1) RU2149646C1 (cg-RX-API-DMAC7.html)
TW (1) TW316905B (cg-RX-API-DMAC7.html)
UA (1) UA42706C2 (cg-RX-API-DMAC7.html)
WO (1) WO1995010304A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA947823B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
WO1998014459A1 (de) * 1996-09-30 1998-04-09 Bayer Aktiengesellschaft Glycokonjugate von modifizierten camptothecin-derivaten (20-o-verknüpfung)
DE19640969A1 (de) * 1996-10-04 1998-04-16 Bayer Ag 20-0-verknüpfte Glycokonjugate von Camptothecin
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
GB9721069D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
GB9721070D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9915180D0 (en) * 1999-06-29 1999-09-01 Pharmacia & Upjohn Spa Antitumour compound
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
AU1820400A (en) * 1999-11-17 2001-05-30 School Of Pharmacy, University Of London, The Conjugates of hpma copolymer and ellipticin
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
GB0008928D0 (en) * 2000-04-11 2000-05-31 Pharmacia & Upjohn Spa A method of administering an antitumour compound
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
US6933302B2 (en) 2002-06-03 2005-08-23 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
ITPD20050242A1 (it) * 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN101265331B (zh) * 2007-03-12 2010-10-13 中国科学院化学研究所 Peg改性phpma材料及其制备方法
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
EP3574922B1 (en) * 2013-04-10 2021-09-15 Syndevrx, Inc. Modified or polymer-conjugated fumagillol metap2 inhibitors for use in improving or restoring insulin sensitivity
JP6529130B2 (ja) * 2013-08-26 2019-06-12 国立研究開発法人科学技術振興機構 接着剤
KR102849342B1 (ko) 2015-12-10 2025-08-21 신데브알엑스, 인크. 푸마길롤 유도체 및 그의 다형체
AU2017206718B2 (en) 2016-01-11 2021-09-30 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
US11612577B2 (en) 2018-10-26 2023-03-28 Syndevrx, Inc. Biomarkers of METAP2 inhibitors and applications thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
GB9309663D0 (en) * 1993-05-11 1993-06-23 Erba Carlo Spa Biologically active compounds

Also Published As

Publication number Publication date
AU679788B2 (en) 1997-07-10
EP0673258B1 (en) 2003-05-07
NZ273952A (en) 1996-10-28
FI952746A0 (fi) 1995-06-05
CN1138565C (zh) 2004-02-18
ATE239507T1 (de) 2003-05-15
CA2150132A1 (en) 1995-04-20
MY116624A (en) 2004-03-31
IL111173A (en) 1998-10-30
PL309328A1 (en) 1995-10-02
KR100359005B1 (ko) 2003-04-26
ES2198421T3 (es) 2004-02-01
UA42706C2 (uk) 2001-11-15
GB9320781D0 (en) 1993-12-01
TW316905B (cg-RX-API-DMAC7.html) 1997-10-01
CN1115564A (zh) 1996-01-24
PT673258E (pt) 2003-09-30
WO1995010304A1 (en) 1995-04-20
ZA947823B (en) 1995-07-03
DE69432627T2 (de) 2004-03-25
HU9502084D0 (en) 1995-09-28
IL111173A0 (en) 1994-12-29
HU215588B (hu) 1999-01-28
US5773522A (en) 1998-06-30
FI952746A7 (fi) 1995-06-05
AU7783694A (en) 1995-05-04
HUT71678A (en) 1996-01-29
JPH08504217A (ja) 1996-05-07
DE69432627D1 (en) 2003-06-12
RU2149646C1 (ru) 2000-05-27
RU95112841A (ru) 1997-06-27
EP0673258A1 (en) 1995-09-27
PL178132B1 (pl) 2000-03-31

Similar Documents

Publication Publication Date Title
FI952746A0 (fi) Polymeeriin sitoutuneen kamptotesiinijohdannaiset
BR9408246A (pt) Composto derivado de 3-azabicicloalcano N-substituído
MX9408969A (es) Composisciones farmaceuticas que comprenden microparticulas biodegradables y biocompatibles para el tratamiento de transtornos psicoticos, su uso y procedimiento para prepararlas.
MD1233B1 (en) Erythromycin derivatives, process for their preparation and pharmaceutical composition on base thereof
TW283716B (cg-RX-API-DMAC7.html)
DE69021176D1 (de) Polypeptid und Verfahren zu dessen Herstellung.
BG103673A (en) 3'-n-oxide, 3'-n-dimethylamine, 9-oxime derivatives of erythromycin a
DK0819132T3 (da) Fremgangsmåde til fremstilling af anthracyclin-antibiotika
EP0450420A3 (en) Dihydropyridines substituted by heterocycles, process for their preparation and their use in medicaments
UA27108A1 (uk) Аhтрацикліhові глікозиди та їх фармацевтичhо прийhятhі кислотhо-адитивhі солі, спосіб їх одержаhhя, похідhі 1,6-дийод-3-оксапеhтаhу та спосіб їх одержаhhя
TW268015B (cg-RX-API-DMAC7.html)
IL125926A0 (en) Compounds related to the amidinium family pharmaceutical compositions containing them and uses thereof
AU6257394A (en) New derivatives of glutamic and aspartic acids, a method of preparing them, and their use as drugs for enhancing memory and learning
IL111725A0 (en) 3'-aziridino-anthracycline derivatives, their preparation and pharmaceutical compositions containing them
IL108856A0 (en) Hydroxymethyl-furazancarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
PH24709A (en) Allylmercaptoacetylsydnonimines and pharmaceutical compositions thereof
NZ315609A (en) 8-N-Anthrazalone derivatives
MY109729A (en) Benzofuranylimidazole derivatives, a process for the preparation and therapeutical compositions containing the same
TR199800340T1 (xx) �n-ila� 6-N-(L-ALA-L-ALA)-trovafloksasin polimorflar�.
DK0874863T3 (da) 3-deoxy-3-descladinose-derivater fra erythromycin A og B
HUP9802072A2 (hu) Benzo-tiopiráno-indazol-származékok és az ezeket tartalmazó gyógyszerkészítmények
ES476077A1 (es) Un procedimiento para preparar derivados del acido 1,3-tia- zol-glioxilico.
MY131175A (en) Heterocyclic compounds
CA2201096A1 (en) Solid dispersion and solid dispersion dosage form of xanthine derivative